 |
University of California, San Francisco |  |
About UCSF | |
Search UCSF | |
UCSF Medical Center |
|
 |
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
|
Dr. Bernstein's clinical activity centers on the inpatient clinical service, including the medical and surgical wards, the Pediatric Intensive Care Unit, and the Intensive Care Nursery. Dr. Bernstein's laboratory studies cell cycle regulation in cardiovascular development and disease. Striated muscle cells cease division within weeks of birth. While skeletal muscle retains limited capacity for regeneration through recruitment of satellite cells, resident populations of adult myocardial stem cells have not definitively been identified. Therefore, damaged myocardium has limited or no ability to regenerate. The Bernstein laboratory’s goal is to understand mechanisms regulating cell division, and how such processes play a role in cardiovascular biology and disease. Their current work is focused on:
1) Efforts toward myocardial regeneration have been limited by the inability of cardiac myocytes to enter mitosis. The lab cloned human CDC5, and demonstrated its functional role in G2/M. More recently, they have defined its site-specific DNA binding properties. Currently, the lab is investigating the role of phosphorylation in regulating CDC5 function. As an adjunct to these studies, they are collaborating on the structural characterization of CDC5 proteins in complex with other macromolecules. These studies will define how CDC5 proteins are regulated and, in turn, regulate the cell cycle. A related line of inquiry focuses on the recent finding that CDC5 family members associate with the pre-mRNA splicing complex, although how this association affects cell cycle progression is not completely understood. Lab members are investigating how human CDC5 participates in pre-mRNA splicing, and how this in turn regulates G2/M transit. They recently reported the domains of CDC5 responsible for nuclear localization and spliceosome association. Future goals of this project will include defining the roles of CDC5 proteins during development and tissue differentiation in higher eukaryotes. 2) Hypertrophy occurs in post-mitotic striated muscle as a response to various stresses in both physiological and pathological situations. While regulation of cyclin-Cdk activities is essential to cell size control in lower eukaryotes, their role in the hypertrophic response in striated muscle is incompletely understood. The lab has demonstrated that hypertrophic stimuli cause a transient burst of Cdk4 activity, remodeling of the retinoblastoma protein complex, and activation of a subset of E2F-1 target genes in murine myoblasts. This has led lab members to identify a physiological role for both E2F-1-mediated activation and repression of genes involved in cell growth versus division, respectively. Currently, the lab is investigating the mechanism(s) by which Cip1/Kip1 and INK4 classes of Cdk-inhibitors facilitate this burst of Cdk4 activity, the role of chromatin remodeling in the hypertrophic response, and identifying other components of the retinoblastoma protein complex that regulate hypertrophy. 3) Because of the lab's interest in muscle regeneration, members specifically are studying the cell cycle withdrawal program in skeletal and cardiac myocytes. The group has developed methods for differentiating mouse and human embryonic stem cells in culture, and selecting ES cell-derived cardiac myocytes. They also have established conditions for differentiating rodent and avian myoblasts into myocytes with spontaneous contractile activity, and for establishing and manipulating primary myoblast cultures. The lab is using these systems to identify regulatory proteins that are differentially expressed in proliferating myoblasts versus post-mitotic myotubes. Primary approaches include subtractive hybridization, expression profiling by microarray analysis, and proteomics. These studies have led to the identification of several proteins that appear to regulate cell cycle withdrawal during muscle differentiation, and current studies focus on elucidating the mechanisms by which these candidate regulators act. 4) Over the past several years, the identification of heterogeneous populations of muscle stem cells in the heart and bone marrow has generated great enthusiasm for new approaches to muscle repair and regeneration. These studies also have exposed the limitations of current strategies. Direct cell replacement has been hindered by the functional isolation observed in transplanted cells. Myogenic differentiation of stem cells has been checked by a low rate of engraftment. Attempts to directly manipulate the myocyte cell cycle have been restrained by the inability of cycling myocytes to complete mitosis. Further understanding of mechanisms that govern cell cycle withdrawal and myoblast fusion during myogenesis is needed to develop methods for expanding populations of fusion-competent muscle cells to treat heart failure and skeletal muscle disorders. To address this need, the lab is studying murine fetal, neonatal, and adult muscle stem cells, as well as human myocardiogenic precursors derived from embryonic stem cells, to determine their origins, mechanisms of self-renewal, and regulation of homing to developing and injured tissues.
|
||||||||||||||||||||
|
|
Harold S. Bernstein, M.D., Ph.D 
